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ABSTRACT 
Polyethylene glycol (PEG) is a gold standard against protein fouling. However, recent studies have 
revealed surprising adverse effects of PEG, namely its immunogenicity and shortened bio-circulation 
upon repeated dosing. This highlights a crucial need to further examine ‘stealth’ polymers for 
controlling the protein ‘corona’, a new challenge in nanomedicine and bionanotechnology. Poly(2-
ethyl-2-oxazoline) (PEtOx) is another primary form of stealth polymer that, despite its excellent 
hydrophilicity and biocompatibility, has found considerably less applications compared with PEG. 
Herein, we performed label-free proteomics to compare the associations of linear PEG- and PEtOx-
grafted nano-graphene oxide (nGO) sheets with human plasma proteins, complemented by 
cytotoxicity and haemolysis assays to compare the cellular interactions of these polymers. Our data 
revealed that nGO-PEG enriched apolipoproteins, while nGO-PEtOx displayed a preferred binding 
with pro-angiogenic and structural proteins, despite high similarities in their respective top-10 
enriched proteins. In addition, nGO-PEG and nGO-PEtOx exhibited similar levels of enrichment of 
complement proteins. Both PEG and PEtOx markedly reduced nGO toxicity to HEK 293 cells while 
mitigating nGO haemolysis. This study provides the first detailed profile of the human plasma protein 
corona associated with PEtOx-grafted nanomaterials and, in light of the distinctions of PEtOx in 
chemical adaptability, in vivo clearance and immunogenicity, validates the use of PEtOx as a viable 
stealth alternative to PEG for nanomedicines and bionanotechnologies.   
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INTRODUCTION  
The rapid development of functional nanomaterials has enabled many advances in diagnostics, 
bioimaging and drug delivery in the past decades.[1, 2] Nanoparticles (NPs) grafted with specific 
polymers such as polyethylene glycol (PEG) become suspended in the aqueous phase and 
biocompatible. PEGylation also discourages protein fouling as the polymer layer acts as an entropic 
spring to fend off the surface adsorption of biomolecules. Collectively, these features have 
consolidated PEGylation as a ‘gold standard’ for surface functionalization in biomedical and 
engineering applications.[3] 
It is well established that NPs readily adsorb a ‘corona’[4-7] of proteins upon introduction into a 
biological milieu, a phenomenon resulting from hydrophobic, electrostatic and van der Waals 
interactions as well as hydrogen bonding between the NPs and proteins in the fluid environment. The 
transformation from bare NPs to NP-protein complexes usually confers the NPs with improved 
suspendability and a new biological identity that drives in vivo interactions and clearance of the NPs.[8, 
9] Binding with NPs could also impact the conformation of adsorbed proteins, thereby inducing 
exposure of new epitopes and potentially altering protein function. For example, activated phagocyte 
recognition of a protein corona via enriched complement components may lead to decreased systemic 
retention for a particular NP,[10, 11] a characteristic undesirable for drug delivery. Accordingly, surface 
functionalization to incorporate ‘stealth’ polymers is a logical solution to minimize and control the 
protein corona for effective design and targeted delivery of nanomedicines.[12] 
PEG is by far the most commonly used polymer for creating ‘stealth’ NPs. However, PEG is not 
biodegradable and the in vivo accumulation of PEGylated therapeutics can cause the production of 
anti-PEG antibodies to accelerate blood clearance and severe hypersensitivity reactions following 
administration.[3, 13-18] In addition, the heavily crowded patent landscape of PEG has also triggered 
intensive search for alternative stealth polymers.[19-21]  
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Poly(2-oxazoline)s (POx) are an emerging class of polymers,[22] which provide access to highly 
functional polymers with tuneable properties simply by changing their side chain.[23, 24] The 
possibility to introduce functional groups at the α-, and ω-polymer chain ends and, contrary to PEG, 
in the side chains makes POx available for a wide range of post-polymerization modifications,[23, 25] 
which can be exploited, e.g. for high drug loadings in polymer-drug conjugates.[26] In particular, the 
short homologues poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx) have 
been demonstrated to be valuable alternatives to PEG with similar water-solubility, biocompatibility 
and stealth/protein repellent properties.[27] Moreover, PMeOx and PEtOx offer potential benefits over 
PEG, including (i) relatively low viscosities of their aqueous solutions, (ii) depending on molecular 
mass, they can be excreted in urine and have so far yet to show accumulations in organs, and (iii) 
they are considered non-immunogenic and to date no POx-antibodies in human populations have been 
reported.[28] In terms of their interaction with proteins, limited studies performed with full serum have 
only looked into the mass deposition of proteins rather than the detailed composition of protein 
corona.[29, 30] One recent study has examined the antifouling capacity of poly(organosiloxane) (POS) 
NPs grafted with linear PEG and PEtOx exposed to fetal calf serum.[31] However, an in-depth 
comparison of the stealth performance and protein corona profile of PEtOx versus PEG against 
human plasma proteins remains lacking despite the large number of studies into POx-based particles 
for biomedical applications and the high relevance of such data for the development of nanomedicine 
and bionanotechnology.[32] Furthermore, research on the protein corona has almost exclusively 
adopted spherical or cylindrical NPs, overlooking the importance of NP shape in determining corona 
formation. Nano-graphene oxide (nGO), specifically, is a one-atom thin, 2D nanomaterial with small 
lateral dimensions and a large surface area. nGO possesses exceptional electronic, photothermal and 
mechanical properties and has found many biomedical applications.[33-39] Here we detail the human 
plasma protein association of a novel nanomaterial, PEtOx-grafted nGO (nGO-PEtOx), in 
comparison with that of PEG-grafted nGO (nGO-PEG). Liquid chromatography coupled to mass 
spectrometry (LC-MS/MS) was used post synthesis for label-free quantitation (LFQ) of proteins 
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present in the NP protein coronas. Although both nGO-PEG and nGO-PEtOx exhibited superior 
antifouling compared to bare nGO, they were each associated with different subsets of plasma 
proteins essential to major physiological functions. In addition to the comparable corona profiles 
observed for high abundance opsonins, there was a significant enrichment of apolipoproteins 
(APOA1/A2/C1/A4/H, CLU) for nGO-PEG, and pro-angiogenic, structural and acute-phase plasma 
proteins for nGO-PEtOx, respectively. Together, this study provides the first report on the unique 
corona proteome in human plasma and in vitro toxicity profiles of nGO-PEG and nGO-PEtOx, 
implicating PEtOx as a viable stealth polymer alternative to PEG for biomedical and biotechnological 
applications. 
 
MATERIALS AND METHODS 
Materials 
A nano-graphene oxide (nGO, ~50×100 nm in lateral dimensions) suspension was obtained from 
Sigma-Aldrich. PEG and PEtOx polymers with amine end groups (MW: 2,000 g/mol) were 
synthesized according to protocols described previously.[40, 41] The polymers were designed to have 
the same molecular weight in order to minimize any size-induced variability. All other chemicals 
were obtained from Sigma-Aldrich and used as received unless otherwise specified. 
NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded using a Bruker UltraShield 400 
spectrometer running Bruker Topspin, version 1.3 and operating at 400.13 MHz for 1H. Deuterated 
chloroform (CDCl3) was used as solvent. Chemical shifts were recorded in parts per million (ppm), 
referenced to residual solvent frequency 1H NMR: CDCl3 = 7.26. 
Size exclusion chromatography  
DMAc size exclusion chromatography (SEC) was performed using a Shimazu modular system 
consisting of a SIL20AD automatic injector, a DGU12A degasser, a CTO10A column oven, a 
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LC10AT pump, a RID10A differential refractive-index detector, and a SPD10A Shimadzu UV/Vis 
detector. A 50×7.8 mm guard column followed by three KF-805L columns in series (300×8 mm linear 
columns, bead size: 10 μm, pore size: 5,000 Å maximum) were used for the analyses. N,N’-
Dimethylacetamide (DMAc, HPLC grade, 0.03% w/v LiBr) with a flow rate of 1 mL/min and a 
constant temperature of 50 °C was used as the mobile phase. The samples were filtered through 0.45 
μm filters prior to injection. The instrument was calibrated using commercially available linear 
polystyrene standards (0.5-2,000 kDa, Polymer Laboratories). Chromatograms were processed using 
Cirrus 2.0 software (Polymer Laboratories).  
nGO functionalization procedures   
nGO (2 mg/mL) was treated with probe sonication for 5 min in an ice bath to ensure its dispersity. 
The first step of the reaction was to convert the OH groups on the nGO surface to –COOH groups via 
conjugation of acetic acid moieties. NaOH (2.4 g) and chloroacetic acid (2.0 g) were added to the 
nGO aqueous suspension (10 mL) and bath-sonicated for 5 h. This step functionalized nGO by 
carboxylation. The carboxylated nGO suspension was then neutralized by repeated washing with 
Milli-Q water through centrifugation (supernatant was removed after each centrifugation cycle). 
Eppendorf centrifuge 5804 was used and set for 10 min and 16,300 g for each washing cycle. Purified 
carboxylated nGO was then diluted with Milli-Q water to an optical density of 0.4 at 808 nm. Then a 
solution of linear PEG or PEtOx with an amine end group (10 mg/mL) was added to the diluted 
carboxylated nGO suspension and the mixture was bath-sonicated for 10 min. Next, N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) was added to make the final EDC 
concentration of 10 mM. The mixture was stirred at room temperature for 24 h, and the reaction was 
terminated by β-mercaptoethanol (50 mM). The mixture was dialyzed in Milli-Q water for 12 h and 
then centrifuged at 16,300 g for 30 min to obtain pure nGO-PEG and nGO-PEtOx from the pellets. 
nGO-PEG and nGO-PEtOx were re-dispersed in Milli-Q water for further use. The concentrations of 
nGO-PEG and nGO-PEtOx were determined by lyophilization. The grafting density of PEG and 
PEtOx polymers was calculated to be ~0.18 and 0.16 polymer chains/nm2, respectively, according to 
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percentage weight losses of the polymers obtained by thermogravimetric analysis (TGA) and the 
physical dimensions of the nGO (50×100 nm, double-sided polymer grafting).  
Thermogravimetric analysis  
Thermogravimetric analysis (TGA) measurement was implemented using a PerkinElmer Pyris 1 
TGA and Pyris 1 software measuring at a rate of 20 °C/min from 100 °C to 700 °C (hold at 100 °C 
for 1 min to eliminate water).  
Dynamic light scattering and zeta potential  
The hydrodynamic sizes and zeta potentials of the nGO suspensions (at 0.1 mg/mL in Milli-Q water) 
were acquired at room temperature using a dynamic light scattering device (Zetasizer Nano ZS, 
Malvern Instruments) with Zeta software 7.03, refractive index 1.33, absorption 0.010, viscosity 
0.8872 cP, temperature 25 °C, and equilibration time 120 s. DTS-1070 cells were used for 
measurements at a backscattered angle of 173° and a wavelength of 633 nm. The measurements were 
carried out for each sample in triplicate, using folded capillary zeta cells. 
Transmission electron microscopy and energy-dispersive X-ray spectroscopy 
nGO (bare nGO , nGO-PEG and nGO-PEtOx) suspensions at a concentration of 0.1 mg/mL were 
pipetted onto glow discharged (15 s) 400 mesh copper grids (Formvar film, ProSciTech) and allowed 
60 s of adsorption. Excess solution volume was drawn off using filter paper and the grids were washed 
twice using Milli-Q water, with excess removed. The grids were stained with 1% uranyl acetate for 
30 s and excess stain drawn off. The grids were completely air-dried. High resolution imaging and 
EDX elemental analysis were performed on a Tecnai G2 F20 transmission electron microscope (FEI, 
Eindhoven, Netherlands) operating at 200 kV. The experiment was repeated three times.  
Infrared spectroscopy 
Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectra were generated using a 
Shimadzu IRTracer 100 FTIR spectrometer with a GladiATR 10 single reflection ATR accessory. 
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The spectra were acquired in the mid-infrared region of 4,000-800 cm-1 at resolution of 8 cm-1 (512 
scans) and analyzed by LabSolution IR software.  
Raman spectroscopy 
Raman spectra were acquired using an inVia confocal Raman microscope (Renishaw). The three 
types of nGO (bare, nGO-PEG- and nGO-PEtOx) with or without plasma protein coatings, as well as 
the plasma protein control in aqueous solution (0.5 mg/mL), were mounted on microscope slides and 
air-dried. The dried samples were excited by a laser line at 785 nm, with a power of 500 mW. Spectra 
were stored with in-built WiRE 2.0 software. 
Collection and processing of healthy donor human plasma proteins 
Details of the method are described in a previous publication.[21] Blood was collected from three 
different healthy donors after obtaining informed consent for any experimentation in this study, in 
accordance with the University of Melbourne Human ethics approval 1443420 and the Australian 
National Health and Medical Research Council Statement on Ethical Conduct in Human Research. 
All experiments were performed in compliance with the relevant laws and institutional guidelines of 
Monash University Occupational Health & Safety. The proteomic experiments and follow-up 
analysis were done using the plasma from the three donors to ensure robust results. The analysis of 
the abundance of coronal proteins was performed by taking average of the three replicates, and only 
those that were statistically significant were presented. 
Corona formation and isolation 
Bare, PEG- and PEtOx-grafted nGO (1 mg/mL) in 10 mM phosphate-buffered saline (PBS) were 
mixed with plasma proteins to make a final concentration of 0.2 mg/mL in 1 mL suspension. The 
nGO-plasma mixtures were incubated at 37 °C for 24 h to obtain hard protein coronae. The samples 
were then centrifuged at 16,300 g for 15 min at room temperature to isolate nGO-‘hard’ protein 
corona complexes from the remaining plasma, a common methodology in the field. The supernatant 
was completely removed and the nGO-protein corona pellets were washed 3× with 10 mM fresh PBS. 
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Following the washes, 50 μL of 5% β-mercaptoethanol (Sigma-Aldrich) in a 4× reducing loading dye 
(240mM Tris, pH 6.8, 8% SDS, 40% glycerol, 0.04% (w/v) bromophenol blue) was added to each 
nGO sample and incubated at 95 °C for 5 min. The nGO samples were pelleted by centrifugation for 
3 min at 21,100 g at 4 °C, and the supernatants (20 μL) of each sample were resolved on a pre-cast 
1D PAGE gel (Mini-PROTEAN® TGXTM, Bio-Rad Laboratories) using 1× mix of a 10× premixed 
electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3, BioRad) at 200 V/0.04 A/8 
W for 5 min. The gel was incubated in Instant Blue stain (Expedion Ltd) for 30 min on a shaker to 
fix and visualize the protein bands. Milli-Q water was then used to de-stain the gel for 1 h (fresh 
Milli-Q water every 20 min) prior to further processing.  
In-gel proteolytic digestion, plasma control sample preparation, LC-MS/MS analysis and label-free 
quantification 
The entire region of the gel containing resolved proteins was excised and subjected to an in-gel trypsin 
digestion procedure, as described previously.[21] Briefly, peptides were extracted, dried in a Speed-
Vac, and stored at -20 °C until analysis. On the day of analysis, samples were reconsituted in 20 μL 
of 2% acetonitrile (ACN), 0.1% formic acid and LC-MS/MS analysis with data-dependent acquisition 
was carried out as previously described with minor modifications.[42] Reconsituted samples were 
loaded at a flow rate of 15 μL/min onto a reversed-phase trap column (100 μm × 2 cm), Acclaim 
PepMap media (Dionex), which was maintained at a temperature of 40 °C . Peptides were then eluted 
from the trap column at a flow rate of 0.25 μL/min through a reversed-phase capillary column (75 
μm × 50 cm) (LC Packings, Dionex). For label-free proteomic analysis, the HPLC gradient was set 
to 98 min using a gradient that reached 30% ACN after 63 min, 34% after 66 min, 79.2% after 71 
min for 6 min, following which there was an equilibration phase of 20 min at 2% ACN. Peptide 
sequences (and protein identity) were determined using MaxQuant software (version 1.6.0.1) by 
matching the human protein database (Homo sapiens, uniprot-proteome_UP000005640.fasta) and 
label free quantification of identified proteins was then performed as previously described.[21] 
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Protein hit filtering methods and significance 
Experiments were replicated three times to assess reproducibility. Only proteins detected in three 
replicates (LFQ intensity > 0) were used for further analyses. LFQ intensity was used to approximate 
the relative protein abundance between the different types of nGOs, while intensity was used to 
represent the protein abundance for each type of nGO individually. A student’s t-test was used to 
evaluate the significance of differences observed across the three independent replicates between 
nGO-PEG and nGO-PEtOx, and p-values < 0.05 were considered significant.  
Protein informatics and network annotation  
The MaxQuant output (protein_groups.csv) was filtered to remove all proteins with less than one 
unique peptide, and with zero values for LFQ intensity across the nGO-PEG and nGO-PEtOx 
experiments. Additional processing included log2 transforms, means, standard deviations, LFQ ratios 
and t-tests. Protein sequences and annotations were extracted from the UniProt Human proteome 
(uniprot-proteome_UP000005640.fasta) by matching to protein identifiers in the filtered protein list. 
For the matched set of protein sequences, the grand average of hydropathy (GRAVY), isoelectric 
point (pI), and molecular weight (MW) were calculated. To produce a contextual human plasma 
proteome background, a non-glycosylated PeptideAtlas build was downloaded (20170801-063918 – 
to recall the results used, visit this link db.systemsbiology.net/sbeams/cgi/shortURL?key=cga2kglb 
– provided in supplementary material) and both the protein identifiers and sequences were extracted 
from the UniProt *.fasta file: GRAVY, pI and MW were calculated for these sequences (as above) 
and used as a background proteome. The complete R data import, processing and presentation code, 
as well as session information that includes computer, software and package versions, are detailed in 
supplementary information.[43, 44]  Proteins were submitted for matching of uniprot identifiers to 
STRING identifiers (http://www.uniprot.org/uploadlists/). The subset of matched STRING 
identifiers were used for protein network analysis with a whole genome background using the online 
resource STRING (v10.5, string-DB.org/).[45] Interactions were defined by database and 
experimentally determined sources at a conﬁdence interaction score of 0.7 (medium). No additional 
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possible interactors were added. Color highlighting was used to emphasize gene ontology (GO) terms 
enriched by the analysis, and color halos were used to indicate PEG- or PEtOx-enrichment. All plots 
were formatted further in InkScape (inkscape.org) or used directly. 
HEK 293 cell viability assay 
For the cell viability assay, nGO, nGO-PEG, nGO-PEtOx, PEG and PEtOx of different concentrations 
were first diluted in PBS to make up stock suspensions. A black/clear bottom Costar 96 well plate 
was coated with poly-L-lysine for 20 min at 37 °C and then washed 3× in DPBS to promote cell 
adhesion. Human embryonic kidney 293 (HEK 293 from ATCC) cells, one of the most commonly 
used cell models for nanotoxicity studies, were seeded at a density of 10,000 cells per well in 200 μL 
complete DMEM (Sigma, 10% FBS) and incubated overnight at 37 °C and 5% CO2. Media was then 
refreshed and samples were added into the wells to make up the final tested concentrations. After 
treatment for 24 h, media was aspirated and wells were washed 3× in DPBS and then 100 μL pre-
diluted (1 in 10 dilution) alamarBlue in media was added to each well. The plate was returned to 
incubator for 3.5 h before endpoint fluorescence was read on a Flexstation 3 plate reader (Molecular 
Devices) with excitation at 544 nm and emission at 590 nm. Percentage cell viability was determined 
as comparative fluorescence intensity to untreated cells after deduction of background fluorescence. 
Experiments were conducted in triplicate. 
Red blood cell (RBC) haemolysis assay  
The haemolysis assay was slightly modified according to previously published protocols.[46, 47] Briefly, 
freshly drawn healthy human donor blood (50 μL) was added to 1.5 mL Eppendorf tubes, containing 
approximately 2.5×108 RBCs. The blood was washed 5× in PBS (pellets centrifuged down using 500 
g and supernatant removed) and then diluted in PBS. Then nGO, nGO-PEG, nGO-PEtOx with and 
without plasma protein corona as well as PEG and PEtOx polymers diluted in PBS were added to the 
tubes containing RBCs to make final concentrations of 100, 50, 20, 10 and 5 μg/mL and incubated at 
37 °C for 2 h. There were no other assay components to interfere with the nGO derivatives interacting 
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with the cells. Following incubation, supernatants (100 μL) of the tubes were transferred to a clear 
bottom Costar 96 well plate and the absorbance was read on a Flexstation 3 plate reader (Molecular 
Devices) at 570 nm (haemoglobin released from haemolytic RBCs). RBCs treated with Milli-Q water 
and PBS alone were used as positive and negative control. Percentage haemolysis was calculated 
from absorbance measured after normalization. Samples containing RBCs (RBCs were fixed by 2.5 % 
paraformaldehyde and PBS was replaced by ethanol using gradient dilution from 20% to 100% of 
ethanol) were mounted on SEM specimen stubs coated with carbon tapes and images were taken 
using an ORION NanoFab scanning helium ion microscope. 
 
RESULTS AND DISCUSSION 
PEG and PEtOx with primary amine end groups (MW ~2000 Da, determined by NMR; Figure S1, 
Electronic Supplementary Information or ESI) were successfully synthesized using a two-step 
reaction according to published protocols (Scheme 1).[40, 41] Size exclusion chromatography (SEC) 
revealed mono-modal traces with narrow molecular weight distributions for both polymers (Đ, PEtOx 
= 1.06, PEG = 1.06, Figure S1). nGO was first functionalized by carboxylation, and then the two 
types of polymers were grafted onto the surface of nGO by N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) coupling.[48, 49] The average lateral dimensions (50×100 nm) 
of bare nGO (carboxylated before polymer grafting) and PEG- and PEtOx-grafted nGO were 
estimated from TEM images (Figure 1). Successful grafting of the polymers was first confirmed using 
ATR-FTIR and energy-dispersive X-ray spectroscopy (EDX) (Figures S2 and S3). ATR-FTIR 
detected the characteristic chemical bond peaks associated with nGO (e.g. OH stretch at 3,340 cm-1) 
and their attached polymers (e.g., ether bond at 1,100 cm-1 for PEG and amide C=O stretch at 1,630 
cm-1 for PEtOx). Although not definitively quantitative, EDX identified nitrogen from the amide bond 
linking nGO to the polymers (apart from the nitrogen from PEtOx) which also confirmed successful 
grafting. To precisely quantify the amount of polymers grafted, TGA was performed on the three 
types of nGO. The grafting density of the polymers was estimated by the percentage weight losses 
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obtained from TGA (Figure S4), where PEG (decomposed from ~307 to 434 °C) and PEtOx 
(decomposed from ~321 to 473 °C) occupied 31.4% and 29.5% of the total mass of nGO-PEG and 
nGO-PEtOx, respectively. The hydrodynamic sizes (z-average sizes) and zeta potentials of bare nGO, 
nGO-PEG and nGO-PEtOx were determined by dynamic light scattering (DLS) (Table 1). The 
hydrodynamic sizes of the PEG- and PEtOx-grafted nGO sheets (318.5 and 291.2 nm, respectively) 
were smaller than bare nGO (364.2 nm), indicating improved suspension due to surface 
functionalization. No large agglomerates were observed for the samples, according to the 
hydrodynamic z-averages of the nGO derivatives measured by DLS. The nGO, nGO-PEG and nGO-
PEtOx were relatively monodisperse, with PDI < 0.3. The zeta potentials ranged from -40.8 mV for 
nGO to -31.4 mV for nGO-PEG and -25.2 mV for nGO-PEtOx, indicating good colloidal 
suspendibility.  
Raman spectra revealed the characteristic G and D bands of all three types of nGO, with the G band 
red-shifted by ~6 and 7 cm-1 in PEGylated and PEtOxylated nGO spectra, respectively. When bare 
nGO, nGO-PEG and nGO-PEtOx were coated with plasma proteins, all the G bands further red-
shifted by ~8, 6 and 7 cm-1, respectively (Figure S5). To determine the composition of plasma proteins 
in the nGO coronas, a proteomic study was undertaken using label-free LC-MS/MS analysis. This 
enabled an in-depth investigation of the antifouling capacities of PEG- and PEtOx-grafted nGO, as 
compared to bare nGO, which was used as a control. Compared to bare nGO, both nGO-PEG and 
nGO-PEtOx bound much smaller amounts of total protein which can be clearly observed from the 
heatmap of a global comparison of the protein abundance levels (Figure S6). Although this confirmed 
the strong antifouling capacities of both PEG and PEtOx, the polymers did bind distinct proteins. The 
LC-MS/MS analysis identified 129 proteins associated with all three types of nGO and 37 unique 
proteins associated with either two or one type of nGO, obtained from three replicate experiments.  
 
The 10 most abundant proteins for bare nGO, nGO-PEG and nGO-PEtOx coronas, as well as for 
plasma, are listed in Table 2. As expected, the abundance distributions of corona proteins associated 
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with the three nGO nanomaterials were different from that of the plasma. For example, serum albumin 
[gene name: ALB (uniprot identifier: P02768)], the most abundant protein in plasma, was the most 
abundant for bare nGO, eighth for nGO-PEG and not in the top 10 for nGO-PEtOx. Overall, PEG 
and PEtOx displayed very comparable binding preferences for the top 10 most abundant proteins, 
which supports the viability of PEtOx as a surface modifier for nano-systems. Key differences in the 
top 10 include the presence of apolipoprotein A-I [APOA1 (P02647)] and serum albumin [ALB  
(P02768)] on nGO-PEG as well as complement C3 [C3 (P01024)] on nGO-PEtOx.  
To more closely evaluate differences in corona composition, unique protein binders were considered. 
The Venn diagram in Figure 2a highlights the numbers of proteins which were bound to one, two, or 
all three nGO types. A total of 17 proteins were unique to one type of nGO, out of which 11 were 
unique to bare nGO (Table 3, Figure 2a). Of the unique nGO-associated proteins, it is worth noting 
that many were immunoglobulins, which suggests that rapid blood clearance of nGO opsonized by 
antibodies may occur without a stealth polymer coating: detected immunoglobulins included IGKV2-
29 (A2NJV5), IGHV6-1 (A0A0B4J1U7), IGKV2-28 (A0A075B6P5), IGLV1-40 (P01703) and 
IGLV3-10 (A0A075B6K4) (Table 3). 
Focusing on relative enrichment of proteins in the evaluated coronas between nGO-PEG and nGO-
PEtOx revealed significant disparities among a number of proteins. The log2 normalized abundance 
ratio of nGO-PEG versus nGO-PEtOx are presented in Figure 2b, with arbitrary ratio thresholds set 
to 0.5 and 2.0. Overall, 15 and 8 proteins were found to be significantly enriched in the corona of 
PEG- and PEtOx-grafted nGO, respectively. Angiogenin [ANG, P03950] exhibited a fold change of 
0.08, or the highest relative affinity for nGO-PEtOx, while vitamin K-dependent protein S [PROS1 
(P07225)] and transthyretin [TTR (P02766)] both exhibited mean fold differences of 6.71, the highest 
relative affinities for nGO-PEG. Some additional proteins enriched on nGO-PEG included multiple 
apolipoproteins – APOA1 (P02647), APOA2 (V9GYM3), APOC1 (K7ERI9), APOA4 (P06727), 
APOH (P02749), CLU (P10909) and the complement proteins CFB (B4E1Z4), CFI (G3XAM2) and 
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C4BPA (P04003) (Table 4). In contrast, nGO-PEtOx enriched pro-angiogenic protein [ANG 
(P03950)], structural protein [FBLN1 (B1AHL2)], acute phase proteins [SAA1 (P0DJI8), SAA2-A4 
(A0A096LPE2)] as well as complement components [C4B (P0C0L5), C8B (F5GY80), C1QC 
(P02747)], making this particle enrichment profile quite distinct from nGO-PEG (Figure 2b, Table 
4).  
A qualitative assessment of calculated – primary sequence specific – characteristics of the corona 
proteins was also undertaken, including GRAVY, pI and MW. Figure 3 shows the GRAVY/pI 
distributions (MW/pI in Figure S7) for the quantified proteins, with point color representing the fold-
change bin to which the log2-normalized ratios of mean PEG: mean PEtOx LFQ intensity value 
belong. These points were overlaid onto a contextualizing non-glycosylated human plasma protein 
background from PeptideAtlas. Here, it was assumed that the matched database sequence for the 
identified protein was identical to that of the nGO-associated protein sequence. The quantified 
proteins appeared to cluster with the general protein characteristics of the plasma background, with 
no major trends apparent. A slight but visually discernible trend included nGO-PEG enriched proteins 
exhibiting more acidic pI values, as compared to nGO-PEtOx. Eight of the top ten nGO-PEG enriched 
proteins (PROS1, TTR, CLU, APOA1, APOC1, SERPINF1, B2M and APOA4) have pI values in the 
range of 5.0-6.5, and the outliers were C4BPA and APOA2. No such trend was apparent for nGO-
PEtOx enriched proteins.  
To further contextualize the relative composition differences of these coronas, a protein network 
analysis was performed using the STRING resource (string-db.org). This allowed identification of 
network associations and associated GO terms. Figure 4 highlights the resulting protein network and 
the colors of the nodes (proteins) indicate enrichment for a particular GO term. Complement 
activation is highlighted in red as an enriched biological process (BP), enzyme regulator activity is in 
blue as an enriched GO molecular function (MF), and finally complement and coagulation cascades 
is in green as an enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The halos 
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in Figure 4 indicate those protein significantly regulated (see red protein ratios in Figure 2b), which 
were enriched on nGO-PEG (yellow) or nGO-PEtOx (black). Both PEG and PEtOx functionalized 
nGO bound complement components that are part of the coagulation cascade (Figure 4). The 
implication here is that both nanomaterials may be similarly susceptible to reduced biocirculation. 
Overall, the split enrichment of different complement and coagulation components by nGO-PEG and 
nGO-PEtOx, and the over-representation of apolipoproteins by nGO-PEG could have profound 
implications in vivo following administration of nGO-based nanomedicines, which should be studied 
in the future. 
Figure 5 shows a comparison of top 10 abundant corona proteins associated with PEGylated and 
PEtOxylated nGO (incubated in human plasma) in the present study with that of POS NPs (incubated 
in fetal calf serum) extracted from the literature.[31] Interestingly, completely different sets of proteins 
were observed between the two different NP cores, even if the surface modifications were similar. 
Serum albumin which is a globular protein is the most abundant corona protein for the spherical POS 
NPs, whereas rod-like fibrinogen represents the highest corona protein level for the 2D nanomaterial 
nGO. This comparison, though of limited validity due to the different experimental conditions 
employed (incubation time, biological media, corona extraction methodologies, etc.), still indicates 
that the shape of NP cores is likely as important as NP surface coating in determining protein binding 
and corona formation. 
In addition to the proteomic study, HEK 293 cell viability was 51.3±7.1% when exposed to 100 
µg/mL of bare nGO (Figure 6a). However, both PEG- and PEtOx-grafted nGO largely ameliorated 
the cell viability to above 80%. In contrast, no obvious toxicity was observed for the three types of 
nGO or the polymers at 50 μg/mL or lower, which confirmed the good biocompatibility of nGO and, 
in particular, stealth polymer-grafted nGO. The RBC haemolysis assay further revealed that both 
nGO-PEG and nGO-PEtOx induced negligible damage to cell membranes, while the presence of 
protein coronas largely mitigated haemolysis induced by nGO, nGO-PEG and nGO-PEtOx at 
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concentrations up to 100 μg/mL (Figure 6b). Images from helium ion microscopy clearly illustrated 
haemolytic damage of RBCs induced by bare nGO (Figure 6d), and the absence of obvious damage 
in the other samples through the protection of plasma proteins (Figure 6g) or stealth polymers PEG 
and PEtOx (Figures 6e,f,h,i). 
 
CONCLUSION 
We have characterized and compared human plasma corona proteome associations of linear PEG- 
and PEtOx-grafted nGO sheets and augmented the examination with viability and haemolysis assays. 
Although ample similarities have been observed for the strong antifouling capacities of both nGO-
PEG and nGO-PEtOx, there were notable differences in the protein corona compositions of the two 
types of nanomaterials. Specifically, nGO-PEG enriched a number of apolipoproteins, suggesting its 
higher affinity for association with lipophilic environments such as cell membranes. In contrast, nGO-
PEtOx displayed a preference for enriching pro-angiogenic, structural binding and acute phase 
proteins, among others. In addition, PEG- and PEtOx-grafted nGO displayed enrichment of different 
complement proteins (CFB, CFI, C4BPA for nGO-PEG, while C4B, C8B, C1QC for nGO-PEtOx) 
indicating comparable phagocytic recognition. Overall, nGO-PEG and nGO-PEtOx showed a very 
similar antifouling capacity, although neither was able to completely prevent protein binding. Both 
nGO-PEG and nGO-PEtOx were biocompatible, as corroborated by the HEK 293 cell viability and 
RBC haemolysis assays. In connection with existing literature, this study has further implicated the 
role of the NP substrate in determining their surface protein enrichment. Together, this study has 
provided a first comprehensive comparison on the stealth capacities and corona composition of PEtOx 
versus PEG against the human plasma proteome and, in light of the advantages of PEtOx over PEG 
in chemical adaptability, low viscosity, clearance, and non-immunogenicity,[28] should prove valuable 
for the continued development of nanomedicine and bionanotechnology. Towards that end, more in-
depth protein corona studies on POx-grafted particles and surfaces will be necessary in the near future 
to gain further insights on the biological effects of the stealth polymer. 
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FIGURES  
 
 
Scheme 1. Synthesis of PEG and PEtOx and their grafting onto nGO (carbon: brown, oxygen: red, 
hydrogen: blue). 
 
 
 
Figure 1. TEM images of the three types of nGO sheets. Scale bars: 100 nm. Pseudo-colors for nGO-
PEG and nGO-PEtOx.  
 
 
 
 
 
 
  
nGO                                 nGO-PEG                         nGO-PEtOx 
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Figure 2. (a) Venn diagram representing the common and unique proteins associated with three nGO 
surface chemistries: bare (nGO), PEG (nGO-PEG) and POx (nGO-PEtOx). The result was acquired 
following 24 h incubation with human plasma proteins. (b) Log2 normalized protein abundance ratio 
plotted against log2 normalized mean (N = 3) nGO-PEG:nGO-PEtOx protein LFQ intensity values 
with arbitrary ratio cut-offs of 0.5 and 2 (dashed black lines). Red dots represent coronal proteins that 
are significantly different in abundance (t-test mean LFQ intensity values) between nGO-PEG and 
nGO-PEtOx. Proteins are identified by their respective unique identifiers.   
(a) (b) 
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Figure 3. The pI vs GRAVY distributions for corona proteins on nGO-PEG and -PEtOx are presented. 
Spot color indicates the abundance bin to which each protein belongs – based on log2 normalized 
ratio of mean LFQ (nGO-PEG):mean LFQ (nGO-PEtOx). The grey dots represent a non-glycosylated 
plasma background from Peptide Atlas (20170801-063918) without abundance information. Proteins 
are annotated with their respective gene names for clarity. GRAVY and pI ranges were manually 
selected. 
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Figure 4. Protein network analysis using the STRING resource (v10.5, string-db.org). The network 
was generated from 82 matched gene name entries (N = 134 total), using experiments and databases 
as active interaction sources, a minimum required interaction score of 0.7 (high confidence), no 
additional interactors and a whole genome background. Gene ontology (GO) annotations generated 
as part of the analysis were added, including complement activation in red (biological process [BP]), 
enzyme regulator activity in blue (molecular function [MF]) and complement and coagulation 
cascades in green (KEGG). Color halos indicate those proteins which were significantly different, 
determined by t-test of mean LFQ intensity values: PEG-enriched are yellow and PEtOx-enriched are 
black. 
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Figure 5. Comparison of top 10 most abundant corona proteins of PEGylated and PEtOxylated nGO 
and that of poly(organosiloxane) (POS) NPs from ref 31. 
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Figure 6. (a) Viability of HEK 293 cells determined using alamarBlue after treatment with different 
concentrations (100, 50, 20 and 10 μg/mL) of nGO, nGO-PEG, nGO-PEtOx, PEG polymer and 
PEtOx polymer for 24 h. Values were expressed as means ± SD (N = 3). (b) Haemolysis assay using 
red blood cells treated with different concentrations (100, 50, 20, 10 and 5 μg/mL) of nGO, nGO-
PEG, nGO-PEtOx w/o plasma protein corona as well as PEG and PEtOx polymers for 2 h. Values 
were expressed as means ± SD (N = 3). Images of red blood cells alone (c) and red blood cells treated 
for 2 h with nGO (d), nGO-PEG (e) and nGO-PEtOx (f) (100 μg/mL) as well as nGO (g), nGO-PEG 
(h), nGO-PEtOx (i) with plasma protein coatings. Images acquired using a scanning helium ion 
microscope. Scale bars: 1 μm.  
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TABLES  
 
Table 1. Zeta potentials and hydrodynamic sizes of the nGO sheets in Milli-Q water. 
Nanomaterials  Zeta potential (mV) Hydrodynamic size (nm) PDI 
nGO -40.8 ± 0.6 364.2 ± 5.6 0.23 ± 0.01 
nGO-PEG -31.4 ± 0.5 318.5 ± 4.8 0.20 ± 0.01 
nGO-PEtOx -25.2 ± 0.5 291.2 ± 4.4 0.22 ± 0.01 
 
 
 
Table 2. Top-10 most abundant proteins associated with each type of nGO. 
No. Bare nGO nGO-PEG nGO-PEtOx Plasma 
1 Serum albumin Fibrinogen alpha chain Fibrinogen alpha chain Serum albumin 
2 Fibrinogen gamma chain Fibrinogen gamma chain Fibrinogen beta chain Ig heavy constant gamma 1 
3 Complement C4-B Fibrinogen beta chain Fibrinogen gamma chain Fibrinogen beta chain 
4 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
Complement C3 
5 Ig heavy constant gamma 1 Ig heavy constant gamma 1 Ig heavy constant gamma 1 Serotransferrin 
6 Fibrinogen alpha chain Apolipoprotein A-I Kininogen-1 Apolipoprotein A-I 
7 Fibrinogen beta chain Gelsolin Gelsolin Alpha-1-antitrypsin 
8 Complement C3 Serum albumin Complement C3 Fibrinogen alpha chain 
9 Gelsolin Kininogen-1 Vitronectin Haptoglobin 
10 Apolipoprotein B-100 Apolipoprotein B-100 Apolipoprotein B-100 Alpha-2-macroglobulin 
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Table 3. Proteins unique to the nGO coronas. 
 Uniprot IDs Gene names Protein names 
Bare nGO A2NJV5 IGKV2-29 Immunoglobulin kappa variable 2-29 
 A0A0B4J1U7 IGHV6-1 Immunoglobulin heavy variable 6-1 
 A0A075B6P5 IGKV2-28 Immunoglobulin kappa variable 2-28 
 P98160 HSPG2 
Basement membrane-specific heparin sulfate proteoglycan 
core protein 
 P06702 S100-A9 Protein S100-A9 
 P01703 IGLV1-40 Immunoglobulin lambda variable 1-40 
 Q14520 HABP2 Hyaluronan-binding protein 2 
 P05109 S100A8 Protein S100-A8 
 E5RH81 CA1 Carbonic anhydrase 1 
 Q9NQ79 CRTAC1 Cartilage acidic protein 1 
 A0A075B6K4 IGLV3-10 Immunoglobulin lambda variable 3-10 
nGO-PEG Q9UGM5 FETUB Fetuin-B 
 Q8WUA8 TSKU Tsukushin 
nGO-PEtOx P48740 MASP1 Mannan-binding lectin serine protease 1 
 P26572 MGAT1 
Alpha-1,3-mannosyl-glycoprotein 2 beta-N-
acetylglucosaminyltransferase 
 Q15485 FCN2 Ficolin-2 
 O15335 CHAD Chondroadherin 
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Table 4. Protein abundance ratio of nGO-PEG versus nGO-PEtOx (less than 0.5 and greater than 2.0 is the fold 
difference threshold, and only proteins that are significantly different between nGO-PEG and nGO-PEtOx are 
listed). 
Uniprot IDs Protein names (Gene names) Mean abundance ratio p value 
P03950 Angiogenin (ANG) 0.08 0.02 
B1AHL2 Fibulin-1 (FBLN1) 0.14  < 0.01 
P0DJI8 Serum amyloid A-1 protein (SAA1) 0.17 0.02 
A0A096LPE2 Serum amyloid A-4 protein (SAA2-A4) 0.28 < 0.01 
P0C0L5 Complement C4-B (C4B) 0.41  < 0.01 
F5GY80 Complement component C8 beta chain (C8B) 0.42 < 0.01 
P34096 Ribonuclease 4 (RNASE4) 0.46  0.01 
P02747 Complement C1q subcomponent subunit C (C1QC) 0.49 0.04 
F5H8B0 Coagulation factor VII (F7) 2.02 < 0.01 
P05546 Heparin cofactor 2 (SERPIND1) 2.23 0.02 
B4E1Z4 Complement factor B (CFB) 2.38  0.01 
G3XAM2 Complement factor I (CFI) 2.44 0.01 
P02749 Apolipoprotein H (APOH) 2.64 0.01 
P06727 Apolipoprotein A-IV (APOA4) 2.82 < 0.01 
P61769 Beta-2-macroglobulin (B2M) 2.89 < 0.01 
P36955 Pigment epithelium-derived factor (SERPINF 1) 2.94 < 0.01 
K7ERI9 Apolipoprotein C-I (APOC1) 3.02 0.02 
V9GYM3 Apolipoprotein A-II (APOA2) 3.34 < 0.01 
P10909 Clusterin (CLU) 3.57 < 0.01 
P02647 Apolipoprotein A-1 (APOA1) 3.91 < 0.01 
P04003 C4b-binding protein alpha chain (C4BPA) 4.35 0.04 
P02766 Transthyretin (TTR) 6.71 < 0.01 
P07225 Vitamin K-dependent protein S (PROS1) 6.71 0.02 
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